5-Benzylidene-3-ethyl-2-thioxothiazolidin-4-one

Name	5-Benzylidene-3-ethyl rhodanine
Synonyms	BTR-1 5-Benzylidene-3-ethyl rhodanine 5-Benzylidene-3-ethyl-2-thioxothiazolidin-4-one 3-Ethyl-5-benzylidene-2-thioxothiazolidin-4-one 4-Thiazolidinone, 3-ethyl-5-(phenylmethylene)-2-thioxo-
CAS	18331-34-5

Molecular Formula	C12H11NOS2
Molar Mass	249.35
Density	1.34±0.1 g/cm3(Predicted)
Melting Point	150 °C
Boling Point	372.8±45.0 °C(Predicted)
pKa	-2.75±0.20(Predicted)
Storage Condition	2-8°C
In vitro study	BTR-1 (10, 50, 100, and 250 µM, 5 days) dose-dependently causes cytotoxicity in human leukemic cells, with IC 50 s of 8 and 6 µM at 48 and 72 h, respectively. Cell Viability Assay Cell Line: T-cell leukemic cell lines Concentration: 10, 50, 100, and 250 µM Incubation Time: 5 days Result: Induced cytotoxicity in human leukemic cells in a dose-dependent manner.

Last Update：2024-01-02 23:10:35

biological activity	BTR-1 is an active anticancer agent, which can induce cell cycle S phase arrest and affect DNA replication. BTR-1 can activate apoptosis (apoptosis), leading to cell death.
target	Apoptosis
in vitro study	BTR-1 (10, 50, 100, and 250 m, 5 days) dose-dependently cytotoxicity in human leukemic cells, with IC 50 s of 8 and 6 m at 48 and 72 h, respectively. Cell Viability Assay Cell Line: T-cell leukemic cell lines Concentration: 10, 50, 100, and 250 m Incubation Time: 5 days Result: induced cytotoxicity in human leukemic cells in a dose-dependent banner.
Cell Line:	T-cell leukemic cell lines
Concentration:	10, 50, 100, and 250 µM
Incubation Time:	5 days
Result:	Induced cytotoxicity in human leukemic cells in a dose-dependent manner.